Get the Stockscreener App
59.65
12.55%
-8.56
After Hours:
59.60
-0.05
-0.08%
Inspire Medical Systems Inc stock is traded at $59.65, with a volume of 4.02M.
It is down -12.55% in the last 24 hours and down -38.46% over the past month.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
See More
Previous Close:
$68.21
Open:
$55.52
24h Volume:
4.02M
Relative Volume:
2.54
Market Cap:
$1.73B
Revenue:
$861.31M
Net Income/Loss:
$53.12M
P/E Ratio:
34.56
EPS:
1.7262
Net Cash Flow:
$85.01M
1W Performance:
-9.07%
1M Performance:
-38.46%
6M Performance:
-28.93%
1Y Performance:
-68.10%
1-Day Range:
$53.11
$64.10
1-Week Range:
$53.11
$71.16
52-Week Range:
$53.11
$197.75
Inspire Medical Systems Inc Stock (INSP) Company Profile
Name
Inspire Medical Systems Inc
Sector
Industry
Phone
763-957-5037
Address
5500 WAYZATA BLVD, GOLDEN VALLEY
Compare INSP vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSP
Inspire Medical Systems Inc
|
59.65 | 1.98B | 861.31M | 53.12M | 85.01M | 1.7262 |
|
ABT
Abbott Laboratories
|
111.47 | 197.52B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
365.85 | 139.09B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
100.88 | 129.59B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.12 | 108.96B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
76.44 | 46.04B | 6.07B | 1.06B | 799.60M | 1.8527 |
Inspire Medical Systems Inc Stock (INSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-22-26 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-22-26 | Downgrade | Truist | Buy → Hold |
| Dec-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-02-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-26-25 | Upgrade | Truist | Hold → Buy |
| Nov-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-24-25 | Upgrade | Stifel | Hold → Buy |
| Nov-04-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-22-25 | Downgrade | UBS | Buy → Neutral |
| Sep-02-25 | Initiated | Evercore ISI | Outperform |
| Aug-05-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-05-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Aug-05-25 | Downgrade | Truist | Buy → Hold |
| Nov-20-24 | Upgrade | BofA Securities | Neutral → Buy |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-19-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-19-24 | Initiated | Morgan Stanley | Overweight |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Jan-19-24 | Initiated | Jefferies | Buy |
| Jan-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Dec-13-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Peer Perform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-15-20 | Downgrade | Goldman | Buy → Neutral |
| Nov-03-20 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-03-20 | Upgrade | Oppenheimer | Underperform → Perform |
| Sep-22-20 | Initiated | JP Morgan | Overweight |
| Sep-02-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-15-20 | Initiated | Goldman | Buy |
| Jun-18-20 | Reiterated | Piper Sandler | Overweight |
| May-18-20 | Initiated | Lake Street | Buy |
| Apr-28-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-09-20 | Initiated | Piper Sandler | Overweight |
| Jan-28-20 | Initiated | Oppenheimer | Underperform |
| Jan-27-20 | Initiated | Oppenheimer | Underperform |
| Nov-06-19 | Upgrade | Berenberg | Sell → Hold |
| Feb-05-19 | Initiated | Dougherty & Company | Buy |
| Nov-28-18 | Initiated | Berenberg | Sell |
| Oct-29-18 | Initiated | Leerink Partners | Outperform |
| May-29-18 | Initiated | Guggenheim | Buy |
| May-29-18 | Initiated | Stifel | Buy |
| May-29-18 | Initiated | Wells Fargo | Outperform |
View All
Inspire Medical Systems Inc Stock (INSP) Latest News
Baird downgrades Inspire Medical stock to Neutral on reimbursement concerns - Investing.com Nigeria
What the FDA’s 2026 Update Means for Wearables - AOL.com
Jefferies Lowers Price Target for INSP, Keeps Hold Rating | INSP Stock News - GuruFocus
Inspire Medical Systems (NYSE:INSP) Price Target Cut to $66.00 by Analysts at Jefferies Financial Group - MarketBeat
Analyst Shagun Singh Maintains Rating for Inspire Medical Systems (INSP) | INSP Stock News - GuruFocus
Inspire Medical: Still A Long Way From A Good Night’s Sleep (NYSE:INSP) - Seeking Alpha
Inspire Medical Systems (INSP) Stock Trades Down, Here Is Why - Finviz
Inspire Medical Systems Lowers FY2026 Revenue Guidance After CMS Coding Clarification, Oppenheimer Says - marketscreener.com
INSP Stock Falls Despite Q4 Earnings Beat, Gross Margin Expands - Yahoo Finance Singapore
Inspire Medical Systems (NYSE:INSP) Shares Gap Down on Analyst Downgrade - MarketBeat
Piper Sandler Lowers Price Target for INSP to $85, Maintains Ove - GuruFocus
INSP: Mizuho Lowers Price Target to $85, Maintains Outperform Ra - GuruFocus
Inspire Medical Systems stock hits 52-week low at $56.17 - Investing.com
INSP Q4 Deep Dive: Reimbursement Uncertainty Shapes Outlook Despite Strong Product Adoption - Finviz
This Inspire Medical Systems Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
Truist Cuts Price Target on Inspire Medical Systems to $70 From $96, Keeps Hold Rating - marketscreener.com
Inspire Medical Systems (NYSE:INSP) Given New $85.00 Price Target at Piper Sandler - MarketBeat
Mizuho Has Lowered Expectations for Inspire Medical Systems (NYSE:INSP) Stock Price - MarketBeat
Inspire Medical Systems, Inc. (NYSE:INSP) Q4 2025 earnings call transcript - MSN
Inspire Medical Systems, Inc. (NYSE:INSP) Q4 2025 Earnings Call Transcript - Insider Monkey
RBC Cuts Price Target on Inspire Medical Systems to $68 From $90, Keeps Sector Perform Rating - marketscreener.com
Baird Downgrades Inspire Medical Systems to Neutral From Outperform, Adjusts Price Target to $74 From $130 - marketscreener.com
Piper Sandler lowers Inspire Medical Systems stock price target on reimbursement concerns By Investing.com - Investing.com India
What 19 Analyst Ratings Have To Say About Inspire Medical Systems - Benzinga
Inspire Medical Stock Pre-Market (-8.7%) : Weak 2026 Revenue Guidance - Trefis
Baird Downgrades Inspire Medical Systems (INSP) and Lowers Price Target | INSP Stock News - GuruFocus
Wells Fargo downgrades Inspire Medical Systems stock rating on reimbursement concerns - Investing.com India
Inspire Medical Systems Q4 2025 Earnings Call Transcript - MarketBeat
Inspire Medical Systems (INSP) Reports Strong Q4 Revenue Growth - GuruFocus
Inspire Medical Systems Q4 Earnings Call Highlights - MarketBeat
Inspire Medical (INSP) Q4 2025 Earnings Transcript - AOL.com
Inspire Medical Systems Q4 2025 slides: revenue hits $912M, projects slower growth - Investing.com India
Earnings call transcript: Inspire Medical Systems Q4 2025 Earnings Beat Forecasts - Investing.com
Despite Q4 beats, Inspire Medical declines on revised 2026 revenue outlook - MSN
Inspire Medical Systems (NYSE:INSP) Stock Plunges on Weak 2026 Outlook Despite Q4 Earnings Beat - ChartMill
Inspire Medical Systems earnings beat by $0.97, revenue topped estimates - Investing.com Canada
Inspire Medical Systems (NYSE:INSP) Posts Better-Than-Expected Sales In Q4 CY2025 But Stock Drops - Finviz
Inspire Medical Systems Q4 Earnings, Revenue Rise - marketscreener.com
Inspire Medical Systems (INSP) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
Inspire Medical Updates Governance, Outlines 2026 Growth Outlook - TipRanks
Inspire Medical shares slide 8% as coding change clouds outlook By Investing.com - Investing.com South Africa
Inspire: Q4 Earnings Snapshot - kare11.com
Inspire Medical shares slide 8% as coding change clouds outlook - Investing.com
Inspire: Q4 Financial Results Overview - Bitget
Inspire Medical (INSP) Exceeds Revenue Expectations in Q4 - GuruFocus
INSP Forecasts FY26 Revenue at $950M to $1B - GuruFocus
Inspire Medical Systems (NYSE:INSP) Posts Quarterly Earnings Results - MarketBeat
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Inspire Medical Systems, Inc. Profit Rises In Q4 - Nasdaq
Inspire Medical Systems: Q4 Earnings Insights - Benzinga
Breakout Watch: Is Inspire Medical Systems Inc benefiting from interest rate changesJuly 2025 Spike Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
Inspire Medical Systems Inc Stock (INSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):